Navigation Links
VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
Date:4/29/2015

Poway, CA (PRWEB) April 29, 2015

The leading Regenerative Veterinary Medicine Company, VetStem Biopharma., is proud to announce that its regenerative stem cell therapy has processed more than 11,000 samples. VetStem was founded in 2002, seeking to discover a successful treatment for horses with potentially fatal injuries to tendons and ligaments.

In 2003 VetStem signed a worldwide exclusive license for adipose-derived (fat derived) stem cell technology for veterinary application, and the first horse was treated in January 2004. Shortly after, the first dogs were treated with VetStem Regenerative Cell Therapy. VetStem started providing stem cell banking to their clients from the beginning so that cells could be stored for future use. By August of 2005 500 horses had been treated. VetStem had effectively introduced a new, natural, injectable treatment to the equine and small animal veterinary industry that could serve as an alternative to euthanasia for some conditions.

Although the large majority of animals treated have been horses, dogs and cats, VetStem has provided services for exotic species as well. The U.S. Navy, Office of Naval Research, awarded VetStem a contract to engage in a collaborative study of stem cell biology in marine mammals in 2009. From this, the first peer-reviewed article was published showing successful isolation of stem cells from dolphin fat. Several media outlets featured a story on a panther from the Tallahassee Museum who received stem cell therapy by VetStem for arthritis of the elbow in 2011. After the therapy he was able to stand up and scratch on his favorite tree with both front paws.

VetStem continues to strive to bring the best Regenerative Medicine therapies to the market to help provide better quality of life for animals. Dr. Robert Harman, CEO and Founder of VetStem has spoken at many human and veterinary conferences sharing the results of real treatments. He has also authored or co-authored numerous peer-reviewed papers on stem cells as well as written book chapters on stem cells.

“I started VetStem in order to help horses with career ending injuries to their tendons and ligaments but so many more animals have been saved from a life of pain or even from euthanasia. I feel privileged and excited to be a part of this therapy that has changed how veterinary medicine is practiced as well as contributing to changes in human medicine,” Robert Harman, DVM, CEO and Founder of VetStem

About VetStem Biopharma.
Since its formation in 2002, VetStem has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, VetStem pioneered the use of regenerative stem cells for horses, dogs, and cats. In 2004 the first horse was treated with VetStem Regenerative Cell Therapy. Ten years later VetStem celebrated its 10,000th animal treated. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at VetStem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the body’s own healing and regenerative cells.

Contact: Kristi Hauta
Marketing Operations Manager
VetStem Biopharma
12860 Danielson Court, Suite B
Poway, CA 92064
858-748-2004 ext 208
khauta@vet-stem.com

Read the full story at http://www.prweb.com/releases/2015/04/prweb12682830.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development
3. PAREXEL Strengthens Commitment To Global Biopharmaceutical Workforce With New PAREXEL Academy Programs
4. PlasmaTech Biopharmaceuticals Appoints Alpha-1 Expert Robert Sandhaus, MD, Ph.D. To Its Scientific Advisory Board
5. PlasmaTech Biopharmaceuticals Provides Strategic Update for 2015 and Review of 2014 Acheivements
6. PlasmaTech Biopharmaceuticals Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea
7. Clinical Researchers and Pharmaceutical Regulatory Affairs Pros Benefit from BioPharma Institute's Newly Accredited Training Programs
8. Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial
9. PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note
10. PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit
11. Synageva BioPharma Reports 2014 Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2020)... ... April 30, 2020 , ... The winners of ... policies, projects, and concepts that are actively engaged and deeply committed to changing ... has taken out the top prize in the Experimental category. , The RASTRUM™ ...
(Date:4/22/2020)... , ... April 20, 2020 , ... ... in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila Berces ... Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role ...
(Date:4/18/2020)... ... April 17, 2020 , ... NeuroFlow has been ... program to support the expansion of its digital health platform enabling behavioral health ... rigorous merit-based review process, adds to NeuroFlow’s recent government awards . , ...
(Date:4/1/2020)... ... March 30, 2020 , ... Kinetic Vet, an ... an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the animal health ... activity against microorganisms for up to 90 days. , In addition to reducing ...
Breaking Biology Technology:
(Date:4/18/2020)... Mass. (PRWEB) , ... April 16, 2020 , ... ... gene and cell therapy, today announced it will present a company update on its ... Virtual Investor Summit taking place on April 22 and 23. Dieter Lingelbach, the ...
(Date:4/15/2020)... ... 15, 2020 , ... NDA Partners Chairman Carl Peck, MD , announced ... Policy Advisor with the Center for Drug Evaluation and Research and former Branch Chief ... has joined the firm as an Expert Consultant. , Dr. Suleiman has expertise in ...
(Date:4/9/2020)... (PRWEB) , ... April 08, 2020 , ... ... Dr. Oligo 768XLc, the most commercially advanced platform for high throughput nucleic acid ... the needs of organizations focused on diagnostic and therapeutic applications for various viruses, ...
Breaking Biology News(10 mins):